Lonza is investing nearly $12 million to expand its biopharmaceutical development services in Singapore. Lonza’s Development Services business provides customized services for the development of robust biomanufacturing processes.
The expansion will add 1,858 m² of lab space and associated equipment, and will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Lonza currently offers these services in its Slough, UK facility with a limited offering in Singapore. The facility is expected to come on-line in by mid-2012.
“This further investment in our Singapore location is driven by the increased demand we are seeing on a global basis,” said Janet White, head of development services at Lonza.
“We are looking forward to offering the full range of our GS Gene Expression System and other technologies in Asia. The location is advantageous to many of our customers from across the globe, and in particular, with our growing set of customers based in the region.”